Another setback, another crash in Mesoblast shares – by 55% this morning

Nick Sundich Nick Sundich, August 4, 2023

Mesoblast shares have crashed again – by 55%. What went wrong this time? In a nutshell, the FDA has told the company it’ll need to conduct another clinical trial for its most advanced stem cell product.




How this point was reached?

The product in question is Remestemcel-L., being developed for inflammatory diseases, particularly acute graft versus host disease (aGVHD), a potentially life-threatening complication of an allogeneic bone marrow transplant (BMT).

Mesoblast wants to enter the US market, something easier said than done as our experience with Cyclopharm (ASX:CYC) has shown. But Cyclopharm has had a cakewalk compared to Mesoblast – even if only because Cyclopharm is already selling its product in many other markets, while Mesoblast has bled tens of millions of dollars of cash to get it’s product off the ground.

Not just trying to appease the FDA and get the necessary clinical data for aGVHD, but it has also contended with class action law suits and a failed attempt to get it approved in relation to COVID-19 (going so far as to start a trial, enrol over 200 patients only to have the US Data Safety Monitoring Board recommend it be wound up due to interim data not holding up).

Mesoblast shares are down ~90% since 2020 and more than 50% on Friday.


Mesoblast shares

Mesoblast (ASX:MSB) share price, log scale (Source: Tradingview)


What happened today to cause the crash in Mesoblast shares?

The FDA told Mesoblast that it would need more data to support approval for remestemcel-L – this means another clinical trial. And the company plans to undertake one. Obviously, this will require even more cash. And this trial will be tougher to get off the ground because it will need to be in the highest-risk adults with the greatest opportunity.

But most importantly, this setback also drained investor confidence that approval will ever happen because it has been so close, but so far many times before. Also keep in mind that the FDA told the company it should do this back in 2020, but MSB ignored it.

Mesoblast’s IR machine has tried to minimise the impact by telling investors there have been no safety issues and that it now has ‘substantial clarity’ about how to proceed. But seeing is believing for long-suffering investors. This is one of the best examples of the ‘catching a falling knife’ trap that investors can fall into, in our view.


Stocks Down Under Concierge is here to help you pick winning stocks!

The team at Stocks Down Under have been in the markets since the mid-90s and we have gone through many ups and downs. We have written about every sector!

Our Concierge BUY and SELL service picks the best stocks on ASX. We won’t just tell you what to buy – we give you a buy range, price target and stop loss level in order to maximise total returns. And we will only recommend very high conviction stocks where substantial due diligence has been conducted.

Our performance is well ahead of the ASX200 and All Ords.

You can try out Concierge … for FREE.




There’s no credit card needed – the trial expires automatically.



Recent Posts

coal be phased out in Australia

When will coal be phased out in Australia? And what will this mean for ASX coal and energy stocks?

When will coal be phased out in Australia? It is inevitable that coal’s days are numbered, although the Russia-Ukraine war…

Woolworths shares

Here are 5 reasons why Woolworths shares aren’t as great an investment as you might think

Woolworths shares may at first glance appear to be one of the most risk-free investments on the ASX. It has…

Australian merger and acquisition laws

Australian merger and acquisition laws will be overhauled in 2026. Is this good or bad for ASX stocks?

Last week, the government introduced changes Australian merger and acquisition laws not seen in nearly 5 decades. The ACCC had…